Internship in Leukemia Research

Published on 06/09/2024

LIH - Luxembourg Institute of Health logo

LIH - Luxembourg Institute of Health


Working time
Type of contract
Spoken languages
EN
Professional experience
Educational level

BACKGROUND

Chronic Lymphocytic Leukemia (CLL) represent the most frequent leukemia in adults. Despite recent advances in treatments, CLL remains a deadly incurable disease. This cancer is caracterized by an accumulation of abnormal, apoptosis resistant, B lymphocytes in the blood and lymphoid organs of the patients. CLL progression is highly dependent on complex interactions between tumor cells and their microenvironment. Indeed, CLL cells can modify stromal cells and immune cells to promote their survival and to escape from the immune surveillance system.


OBJECTIVES

Our team focuses on the mechanisms leading to leukemia progression, in particular the influence of CLL cells on stromal cells and immune cells located in their microenvironment, with the goal to identify new prognostic markers and therapeutic targets.


TRAINING AND RESEARCH ENVIRONMENT

Tumor Stroma Interactions research group is a dynamic and multinational team whose current members originate from France, Belgium, Luxembourg, Spain, Germany, Italy and Argentina. It belongs to the Department of Cancer Research, whose research activities focus on the cellular and molecular mechanisms of tumor progression using a wide range of cutting edge technologies, including genomic, transcriptomic and proteomic analyses, as well as in vitro and in vivo imaging modalities using state-of-the art animal models for cancer ;The post-doctoral researcher will be working on a large FNR CORE-funded project that aims to explore the complex interplay between CLL cells and immune cells in the microenvironment, and will be co-supervised by ;E. Moussay (PI) and Dr. J. Paggetti (PI).


Recent related references (open access): Gargiulo, E., Viry, E., Morande, P. E. et ;Extracellular Vesicle Secretion by Leukemia Cells In Vivo Promotes CLL Progression by Hampering Antitumor T-cell Responses. Blood Cancer Discov 4, 54-77 (2023).


GENDER EQUALITY

The LIH is an equal opportunities employer. We are fully committed to removing any discriminatory barrier related to gender, and not only, in recruitment and career progression of our staff. The LIH is attentive to gender representation among its leadership staff and aims to eliminate obstacles to the recruitment and promotion of female leaders and their career development.

LIH - Luxembourg Institute of Health logo

LIH - Luxembourg Institute of Health

1A-B, rue Thomas Edison
L-1445 Strassen
Luxembourg

Career LIH - Luxembourg Institute of Health

Internship in Leukemia Research

Come meet us

Unicareers Luxembourg

Friday 27 September 2024 Luxembourg

LIH - Luxembourg Institute of Health will be participating in the next Unicareers. Come meet your next potential employer and increase your chance of being hired.

Register for the event
Let’s meet on
September 27 😍